Denali Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
DNLI$19.85-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net loss | $(308,020) | $(25,751) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 5,942 | 14,549 |
| Stock–based compensation expense | 77,800 | 82,114 |
| Net accretion of discounts on marketable securities | (28,952) | (31,709) |
| Non-cash adjustment to operating lease expense | (3,025) | (2,762) |
| Right-of-use asset amortization for finance lease | 431 | — |
| Non-cash gain from divestiture of small molecule programs | (14,537) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (2,625) | 1,910 |
| Other non-current assets | (1,178) | — |
| Accounts payable | 151 | 4,512 |
| Accruals and other current liabilities | 6,090 | (11,665) |
| Related-party contract liability | — | (290,532) |
| Deferred research and development funding liability, less current portion | 3,944 | — |
| Net cash used in operating activities | (263,979) | (259,334) |
| Investing activities | ||
| Purchases of marketable securities | (1,056,263) | (1,399,982) |
| Maturities and sales of marketable securities | 806,120 | 1,586,947 |
| Purchases of property and equipment | (10,820) | (10,704) |
| Net cash (used in) provided by investing activities | (260,963) | 176,261 |
| Financing activities | ||
| Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs of $480K | 499,253 | — |
| Proceeds from exercise of awards under equity incentive plans | 13,234 | 13,115 |
| Payments for finance lease right-of-use asset | (24,015) | — |
| Net cash provided by financing activities | 488,472 | 13,115 |
| Net decrease in cash, cash equivalents and restricted cash | (36,470) | (69,958) |
| Cash, cash equivalents and restricted cash at beginning of period | 128,681 | 219,544 |
| Cash, cash equivalents and restricted cash at end of period | $92,211 | $149,586 |
| Supplemental disclosures of cash flow information | ||
| Increase in right-of-use asset due to lessor assets | $7,051 | $— |
| Non-cash recognition of new finance lease | $5,689 | $— |
| Cash paid for finance lease interest | $121 | $— |
| Cash paid during the period for income taxes | $— | $4 |
| Equity consideration received in the divestiture of small molecule programs (Note 10) | $15,000 | $— |
| Property and equipment purchases accrued but not yet paid | $263 | $6,230 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.